VENUS REMEDIES Financial Statement Analysis
|
||
The Revenues of VENUS REMEDIES have increased by 7.72% YoY .
The Earnings Per Share (EPS) of VENUS REMEDIES has increased by 59.08 % YoY. |
REVENUES |
OPERATING MARGIN |
PROFIT AFTER TAX |
EPS |
ROCE |
VENUS REMEDIES Last 5 Annual Financial Results
[BOM: 526953|NSE : VENUSREM]
Consolidated | Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 |
---|---|---|---|---|---|
Revenues | ₹648 Cr | ₹601 Cr | ₹556 Cr | ₹600 Cr | ₹548 Cr |
Expenses | ₹584 Cr | ₹542 Cr | ₹495 Cr | ₹538 Cr | ₹494 Cr |
Operating Profit (Excl OI) | ₹64 Cr | ₹60 Cr | ₹60 Cr | ₹62 Cr | ₹54 Cr |
Other Income | ₹21 Cr | ₹12 Cr | ₹10 Cr | ₹8.31 Cr | ₹20 Cr |
Interest | ₹0.07 Cr | ₹0.09 Cr | ₹0.12 Cr | ₹0.48 Cr | ₹13 Cr |
Depreciation | ₹23 Cr | ₹26 Cr | ₹32 Cr | ₹34 Cr | ₹35 Cr |
Profit Before Tax | ₹72 Cr | ₹45 Cr | ₹38 Cr | ₹36 Cr | ₹49 Cr |
Profit After Tax | ₹45 Cr | ₹28 Cr | ₹27 Cr | ₹41 Cr | ₹62 Cr |
Consolidated Net Profit | ₹45 Cr | ₹28 Cr | ₹27 Cr | ₹41 Cr | ₹62 Cr |
Earnings Per Share (Rs) | ₹33.90 | ₹21.31 | ₹19.87 | ₹30.47 | ₹50.04 |
PAT Margin (%) | 6.99 | 4.74 | 4.78 | 6.79 | 11.27 |
ROE(%) | 8.64 | 6.01 | 5.90 | 9.85 | 17.40 |
ROCE(%) | 13.17 | 8.67 | 7.72 | 7.89 | 12.37 |
Total Debt/Equity(x) | 0.00 | 0.08 | 0.09 | 0.10 | 0.13 |
Key Financials |
||
Market Cap | : | ₹ 632.5 Cr |
Revenue (TTM) | : | ₹ 671.2 Cr |
Net Profit(TTM) | : | ₹ 53.7 Cr |
EPS (TTM) | : | ₹ 40.1 |
P/E (TTM) | : | 11.8 |
Industry Peers & Returns | 1W | 1M | 1Y |
VENUS REMEDIES | -3.5% | -10% | 22.3% |
SUN PHARMACEUTICAL INDUSTRIES | 3.5% | -3.4% | -5.8% |
DIVIS LABORATORIES | 3.7% | -10.2% | 25.6% |
CIPLA | 5.3% | 6.1% | -1.3% |
TORRENT PHARMACEUTICALS | 1.4% | 4.6% | 7.6% |
DR REDDYS LABORATORIES | 3.9% | 0% | -9.9% |
MANKIND PHARMA | 0.3% | -5.8% | 13.5% |
ZYDUS LIFESCIENCES | 5.7% | 2.1% | -15.9% |
LUPIN | 2.3% | 1.6% | -5.3% |
VENUS REMEDIES Revenues
[BOM: 526953|NSE : VENUSREM]
Y-o-Y | 7.72 % |
5 Yr CAGR | 4.27 % |
Years | Revenues | % Change | |
---|---|---|---|
Mar2025 | ₹648 Cr | 7.72 | |
Mar2024 | ₹601 Cr | 8.27 | |
Mar2023 | ₹556 Cr | -7.44 | |
Mar2022 | ₹600 Cr | 9.50 | |
Mar2021 | ₹548 Cr | - |
VENUS REMEDIES Operating Profit
[BOM: 526953|NSE : VENUSREM]
Y-o-Y | 6.59 % |
5 Yr CAGR | 4.25 % |
Years | Operating Profit | % Change | |
---|---|---|---|
Mar2025 | ₹64 Cr | 6.59 | |
Mar2024 | ₹60 Cr | -0.71 | |
Mar2023 | ₹60 Cr | -3.36 | |
Mar2022 | ₹62 Cr | 15.50 | |
Mar2021 | ₹54 Cr | - |
Operating Margins | |
---|---|
Y-o-Y | -1.01 % |
5 Yr CAGR | 0.00 % |
Years | Operating Margin% | % Change | |
---|---|---|---|
Mar2025 | 9.81% | -1.01 | |
Mar2024 | 9.91% | -8.33 | |
Mar2023 | 10.81% | 4.44 | |
Mar2022 | 10.35% | 5.50 | |
Mar2021 | 9.81% | - |
VENUS REMEDIES Profit After Tax
[BOM: 526953|NSE : VENUSREM]
Y-o-Y | 59.05 % |
5 Yr CAGR | -7.45 % |
Years | Profit After Tax | % Change | |
---|---|---|---|
Mar2025 | ₹45 Cr | 59.05 | |
Mar2024 | ₹28 Cr | 7.25 | |
Mar2023 | ₹27 Cr | -34.77 | |
Mar2022 | ₹41 Cr | -34.07 | |
Mar2021 | ₹62 Cr | - |
PAT Margins | |
---|---|
Y-o-Y | 47.47 % |
5 Yr CAGR | -11.26 % |
Years | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2025 | 6.99 % | 47.47 | |
Mar2024 | 4.74 % | -0.84 | |
Mar2023 | 4.78 % | -29.60 | |
Mar2022 | 6.79 % | -39.75 | |
Mar2021 | 11.27 % | - |
VENUS REMEDIES Earnings Per Share (EPS)
[BOM: 526953|NSE : VENUSREM]
Y-o-Y | 59.08 % |
5 Yr CAGR | -9.28 % |
Years | EPS | % Change | |
---|---|---|---|
Mar2025 | ₹34 | 59.08 | |
Mar2024 | ₹21 | 7.25 | |
Mar2023 | ₹20 | -34.79 | |
Mar2022 | ₹30 | -39.11 | |
Mar2021 | ₹50 | - |
VENUS REMEDIES Return on Capital Employed (ROCE)
[BOM: 526953|NSE : VENUSREM]
Y-o-Y | 51.90 % |
5 Yr CAGR | 1.58 % |
Years | ROCE | % Change | |
---|---|---|---|
Mar2025 | 13.17% | 51.90 | |
Mar2024 | 8.67% | 12.31 | |
Mar2023 | 7.72% | -2.15 | |
Mar2022 | 7.89% | -36.22 | |
Mar2021 | 12.37% | - |
VENUS REMEDIES Share Price vs Sensex
Current Share Price | : | ₹472.1 |
Current MarketCap | : | ₹ 632.5 Cr |
Updated EOD on | : | Aug 14,2025 |
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
VENUS REMEDIES | -3.5% |
-10% |
22.3% |
SENSEX | -0% |
-2.4% |
1.2% |
VENUS REMEDIES related INDICES
You may also like the below Video Courses
FAQ about VENUS REMEDIES Financials
How the annual revenues of VENUS REMEDIES have changed ?
The Revenues of VENUS REMEDIES have increased by 7.72% YoY .
How the Earnings per Share (EPS) of VENUS REMEDIES have changed?
The Earnings Per Share (EPS) of VENUS REMEDIES has increased by 59.08 % YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs